These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Dual targeting of the epigenome via FACT complex and histone deacetylase is a potent treatment strategy for DIPG. Ehteda A; Simon S; Franshaw L; Giorgi FM; Liu J; Joshi S; Rouaen JRC; Pang CNI; Pandher R; Mayoh C; Tang Y; Khan A; Ung C; Tolhurst O; Kankean A; Hayden E; Lehmann R; Shen S; Gopalakrishnan A; Trebilcock P; Gurova K; Gudkov AV; Norris MD; Haber M; Vittorio O; Tsoli M; Ziegler DS Cell Rep; 2021 Apr; 35(2):108994. PubMed ID: 33852836 [TBL] [Abstract][Full Text] [Related]
5. Transcriptional Dependencies in Diffuse Intrinsic Pontine Glioma. Nagaraja S; Vitanza NA; Woo PJ; Taylor KR; Liu F; Zhang L; Li M; Meng W; Ponnuswami A; Sun W; Ma J; Hulleman E; Swigut T; Wysocka J; Tang Y; Monje M Cancer Cell; 2017 May; 31(5):635-652.e6. PubMed ID: 28434841 [TBL] [Abstract][Full Text] [Related]
6. Targeting AXL overcomes resistance to docetaxel therapy in advanced prostate cancer. Lin JZ; Wang ZJ; De W; Zheng M; Xu WZ; Wu HF; Armstrong A; Zhu JG Oncotarget; 2017 Jun; 8(25):41064-41077. PubMed ID: 28455956 [TBL] [Abstract][Full Text] [Related]
7. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161 [TBL] [Abstract][Full Text] [Related]
8. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG. Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026 [TBL] [Abstract][Full Text] [Related]
9. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells. Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499 [TBL] [Abstract][Full Text] [Related]
10. Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype. Ciardiello D; Blauensteiner B; Matrone N; Belli V; Mohr T; Vitiello PP; Martini G; Poliero L; Cardone C; Napolitano S; De Falco V; Giunta EF; Ciaramella V; Corte CD; Barra G; Selvaggi F; Franco R; Marino FZ; Cuomo A; Morgillo F; Troiani T; Sibilia M; Ciardiello F; Martinelli E Med Oncol; 2021 Feb; 38(3):24. PubMed ID: 33570712 [TBL] [Abstract][Full Text] [Related]
11. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162 [TBL] [Abstract][Full Text] [Related]
12. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression. von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482 [TBL] [Abstract][Full Text] [Related]
13. Small-Molecule Inhibition of Axl Targets Tumor Immune Suppression and Enhances Chemotherapy in Pancreatic Cancer. Ludwig KF; Du W; Sorrelle NB; Wnuk-Lipinska K; Topalovski M; Toombs JE; Cruz VH; Yabuuchi S; Rajeshkumar NV; Maitra A; Lorens JB; Brekken RA Cancer Res; 2018 Jan; 78(1):246-255. PubMed ID: 29180468 [TBL] [Abstract][Full Text] [Related]
14. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction. Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766 [TBL] [Abstract][Full Text] [Related]
15. Single-Cell Proteomic Profiling Identifies Combined AXL and JAK1 Inhibition as a Novel Therapeutic Strategy for Lung Cancer. Taverna JA; Hung CN; DeArmond DT; Chen M; Lin CL; Osmulski PA; Gaczynska ME; Wang CM; Lucio ND; Chou CW; Chen CL; Nazarullah A; Lampkin SR; Qiu L; Bearss DJ; Warner S; Whatcott CJ; Mouritsen L; Wade M; Weitman S; Mesa RA; Kirma NB; Chao WT; Huang TH Cancer Res; 2020 Apr; 80(7):1551-1563. PubMed ID: 31992541 [TBL] [Abstract][Full Text] [Related]
16. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer. Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120 [TBL] [Abstract][Full Text] [Related]
17. Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia. Ben-Batalla I; Erdmann R; Jørgensen H; Mitchell R; Ernst T; von Amsberg G; Schafhausen P; Velthaus JL; Rankin S; Clark RE; Koschmieder S; Schultze A; Mitra S; Vandenberghe P; Brümmendorf TH; Carmeliet P; Hochhaus A; Pantel K; Bokemeyer C; Helgason GV; Holyoake TL; Loges S Clin Cancer Res; 2017 May; 23(9):2289-2300. PubMed ID: 27856601 [No Abstract] [Full Text] [Related]